Related Experiment Video
Updated: Jun 19, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Sodium-Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
Yixuan Fang1,2, Lihong Chen1,2, Shiyi Sun1,2
1Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Journal of Cardiovascular Development and Disease
|July 26, 2024
Summary
Sodium-dependent glucose transporter 2 inhibitors show clear benefits for heart failure hospitalization. These drugs may also benefit cardiovascular death and renal outcomes, but carry a risk of genital infection.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are increasingly recognized for their therapeutic potential in heart failure management.
- Existing research highlights the efficacy of SGLT2 inhibitors in treating various cardiovascular conditions.
Purpose of the Study:
- To systematically review and evaluate the efficacy and safety of SGLT2 inhibitors in the treatment of heart failure.
- To synthesize evidence from multiple systematic reviews on SGLT2 inhibitors for heart failure.
Main Methods:
- A comprehensive systematic search of eight electronic databases was conducted up to July 2023.
- Methodological quality, reporting quality, risk of bias, and quality of evidence were assessed using established tools (AMSTAR 2, PRISMA 2020, ROBIS, GRADE).
Main Results:
- Thirty-six systematic reviews were included in the analysis.
- Clear benefits were observed for reducing heart failure hospitalizations.
- Possible benefits included reduced cardiovascular death and improved renal outcomes, with a possible harm of genital infections.
Conclusions:
- SGLT2 inhibitors demonstrate significant benefits in managing heart failure, particularly in reducing hospitalizations.
- The evidence supports their use, though careful consideration of potential harms like genital infections is warranted.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
01:32Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:17Oral Hypoglycemic Agents: Sulfonylureas
198
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
198
01:26Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555